NAD replenishment therapy for atypical parkinsonism

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of oral Nicotinamide Riboside (NR) on patients with atypical parkinsonism, specifically targeting Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Corticobasal Syndrome (CBS). The study aims to boost cellular NAD levels in the central nervous system, potentially delaying disease progression and alleviating symptoms. A total of 130 patients will be enrolled, and participants will be randomly assigned to receive either NR or a placebo. The trial will assess the neuroprotective effects of NR through various clinical evaluations and imaging techniques.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participant must understand the nature of the study and be able to provide written, informed consent.
2. Male or female aged 30-85 years at baseline.
3. 123I-Ioflupane dopamine transporter imaging (DaTSCAN) or FDOPA- PET has been performed. A negative DaTSCAN cannot be more than two years old at baseline.
4. Meet the MDS criteria for possible or probable PSP; or
5. Meet the MDS criteria for clinically possible or probable MSA; or
6. Meet the consensus criteria for probable or possible CBS.
7. A baseline PSPRS score of \<40 for PSP, or baseline UMSARS score \< 3 on items: 1, 2, 7-9.
8. Score ≥ 20 on the Mini-Mental State Examination (MMSE) at screening.
9. Able to ambulate independently or with assistance defined as the ability to take at least 5 steps with a walker (guarding is allowed provided there is no contact) or the ability to take at least 5 steps with the assistance of another person who can only have contact with one upper extremity.

Exclusion Criteria:

1. Insufficient fluency in local language to complete neuropsychological and functional assessments.
2. Evidence of differential diagnoses to PSP, MSA or CBS including: PD; dementia with Lewy bodies; Alzheimer's disease; motor neuron disease; history of repeated and/or major stroke; history of repeated and/or severe brain or spinal cord; history of neuroleptic use (except quetiapine) for prolonged period within the last 6 months; history of severe encephalitis; street drug-related parkinsonism; vascular parkinsonism; familial PSP, FTD, or known pathogenic MAPT mutation; prion disease; other neurological disease or MRI findings that could explain the PSP, MSA or CBS symptoms.
3. Presence of other significant neurological or psychiatric disorders including (but not limited to) psychotic disorders; severe bipolar or unipolar depression; seizure disorder; tumor or other space-occupying lesion.
4. Treatment with/use of NR or any investigational drugs or device, within 90 days of screening.
5. A history of alcohol or substance abuse within 1 year prior to baseline (Visit 1) and deemed to be clinically significant by the site investigator
6. Any active neoplastic malignancy (other than non-metastatic dermatological conditions) within two years of the screening visit (Visit 0) or current clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal, or neurological disease. Active neoplastic malignancy is defined as having a known malignant focus and/or receiving anti-cancer treatment. For the non-cancer conditions, if the condition has been stable for at least the one year before the screening visit (Visit 0) and/or is judged by the site investigator not to interfere with the subject's participation in the study, the subject may be included.
7. Clinically significant laboratory abnormalities at screening that cannot be corrected to baseline and that is deemed incompatible with study participation by investigator.
8. History of deep brain stimulator surgery other than sham surgery for deep brain stimulation (DBS) clinical trial.
9. History of a clinically significant medical condition that would interfere with the subject's ability to comply with study instructions, would place the subject at increased risk, or might confound the interpretation of the study results.
10. Severe dysphagia with inability to swallow study-drug safely at baseline.

Where it's running

• Oslo University Hospital
  Oslo, Oslo, Norway Recruiting
• Haukeland University Hospital
  Bergen, Vestland, Norway Recruiting
• Vestre Viken HF
  Drammen, Norway Recruiting

Study contacts

• Study coordinator: Geir Olve Skeie, MD, Dr.med
• Email: geir.olve.skeie@helse-bergen.no
• Phone: 55975045

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Genetic program for Progressive Supranuclear Palsy and related conditions

  This study is collecting DNA from adults with Progressive Supranuclear Palsy and similar conditions to see how genetics might help improve diagnosis and care for patients.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT06647641

• Personalized magnetic brain stimulation for parkinsonian disorders

  This study will try personalized repetitive transcranial magnetic stimulation (rTMS) to see if it eases motor and non-motor symptoms in people with Parkinson's disease, multiple system atrophy, or progressive supranuclear palsy.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07570212

• Examining health services and quality of life in patients with atypical Parkinsonian syndromes

  This study looks at how people with atypical Parkinsonian syndromes, like progressive supranuclear palsy and multiple system atrophy, use health services and how their quality of life is affected by having access to specialist clinics and support services.

  Recruiting University Hospital Southampton NHS Foundation Trust · Southampton, Hampshire · NCT06645626

• Predicting disease progression in dementia using biomarkers and modeling

  This study is trying to create a tool that helps predict how dementia will progress in people with mild cognitive impairment and different types of dementia, like Alzheimer's and Lewy Body Disease, by looking at brain scans, body fluids, and mental tests.

  Recruiting University Health Network, Toronto · North York, Ontario and 3 other locations · NCT06529744

• Biobank for studying ALS and Alzheimer's diseases

  This study is collecting blood, skin samples, and health information from people to see how genetics might help us understand and find treatments for ALS and Alzheimer's disease.

  Recruiting New York Stem Cell Foundation Research Institute · New York, New York · NCT06203106

• Using a non-invasive device to help manage symptoms in people with Parkinson's disease

  This study is testing a new device that uses gentle vibrations to see if it can help people with Parkinson's disease feel better and manage their symptoms.

  Recruiting Queen Mary University of London · London · NCT06174948

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.